Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol Oral Solution for Refractory Infantile Spasms
NCT02551731Phase 2Terminated
- Sponsor
- Insys Therapeutics
- Start
- Jan 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in infantile epileptic spasms syndrome (IESS), sponsored by Insys Therapeutics. Primary endpoints: Percentage of Participants Who Are Considered Complete Responders at Day 14 and Percentage of Participants Experiencing Adverse Events (AEs), Treatment-Emergent AEs (TEAEs), and Serious Adverse Events (SAEs). Started Jan 2016; status: terminated.
02
Drugs
cannabidiol
03
Conditions
infantile epileptic spasms syndrome (IESS)
Beyond the preview
Go deeper on NCT02551731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02551731.